Pharma Strategy and Competitive Intelligence

Glioblastoma multiforme is by far the most common and most malignant of the glial tumors, yet prognosis remains poor. Less than 5% of patients survive 5 years after diagnosis. Preliminary data was recently reported at a cancer conference on an investigational compound has shown promise in prolonging survival among patients with recurrent glioblastoma. This compound, [...]

[Read more →]